Acelot, founded in Santa Barbara, is a life science R&D company dedicated to revolutionizing drug discovery, particularly for neurodegenerative disorders. The company offers an advanced web-based drug discovery platform that leverages generative AI, machine learning, in-house assays, and molecular dynamic simulations. This technology enables the identification of latent pharmacophore information and facilitates rapid drug development even in the absence of clear target information or crystallography data.

Notable figures affiliated with Acelot include Katie Planey, who holds the titles of CEO, MBA, and PhD. The company has made significant strides in the biopharmaceutical sector by combining cutting-edge AI and molecular simulations to address complex neurodegenerative conditions. Acelot's innovative approach has positioned it as a key player in the drug discovery market, contributing to advancements in therapies for diseases where traditional methods fall short.